Out-of-pocket costs of HAART limit HIV treatment responses in Botswana's private sector
- 12 June 2006
- journal article
- Published by Wolters Kluwer Health in AIDS
- Vol. 20 (9) , 1333-1336
- https://doi.org/10.1097/01.aids.0000232245.36039.2b
Abstract
A large number of HIV-infected patients in sub-Saharan Africa pay out-of-pocket for HAART. This analysis from Botswana indicates that higher median out-of-pocket regimen costs to patients for the initial 30 days of HAART are associated with failure to achieve a viral load< 400 copies/ml [US$32; interquartile range (IQR), 20-84 compared with US$22; (IQR, 17-36), P = 0.001]. HAART costs should be minimized as scale-up efforts in sub-Saharan Africa progress.Keywords
This publication has 10 references indexed in Scilit:
- Efficacy of Antiretroviral Therapy Programs in Resource‐Poor Settings: A Meta‐analysis of the Published LiteratureClinical Infectious Diseases, 2005
- Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapyInternational Journal of STD & AIDS, 2005
- Costs attributable to AIDS at household level in ChadAIDS Care, 2004
- Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2004
- Barriers to Antiretroviral Adherence for Patients Living with HIV Infection and AIDS in BotswanaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2003
- Adherence to HAART and its principal determinants in a cohort of Senegalese adultsAIDS, 2003
- Antiretroviral use in Ouagadougou, Burkina FasoAIDS, 2003
- Antiretroviral treatment in developing countries: the peril of neglecting private providersBMJ, 2003
- Antiretroviral therapy in the private sector of Nairobi, KenyaAIDS, 2003
- Cheaper antiretrovirals to treat AIDS in South AfricaBMJ, 2000